Metastatic or Recurrent Head & Neck Cancer: New Hope with Immunotherapy

Ehteshamul Hoque^1, and Safayet Hossain²

¹Senior Consultant, Department of Radiotherapy, Labaid Cancer Hospital & Amp, Super Specialty Center, Dhaka, Bangladesh

²Manager, Oncology, Beacon Pharmaceuticals Limited, Dhaka, Bangladesh

Cite this paper:
Ehteshamul Hoque and Safayet Hossain. Metastatic or Recurrent Head & Neck Cancer: New Hope with Immunotherapy. American Journal of Cancer Prevention. 2023; 10(1):12-13. doi: 10.12691/ajcp-10-1-3

Abstract

Introduction: The recurrence of any type of cancer can be a great physical, mental and financial burden for the patients, and can also negatively impact the overall health status of a country. Despite the availability of multiple treatment methods, patients with recurrence of cancer still show up. Which is why, the present study of 2 recurrent carcinoma patients, who after being treated with immunotherapy, did no see any recurrence and observed significant clinical and radiological improvement, is of great importance. Case Presentation: This study was conducted with 2 cases of recurrent head and neck cancer, both of whom were Bangladeshi female. The first patient was 70-year-old, while the second patient was 59 years old. Both had received multiple previous treatment, including surgical treatment and chemotherapy, but still had recurrence of cancer. Conclusion: The use of immunotherapy in recurring Head & Neck Cancer shows promising Clinical and Radiological response, with much fewer observable side-effects compared to previous treatment methods.

Keywords:
cancer carcinoma immunotherapy chemotherapy chemoradiotherapy

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	What Is Cancer? (2007) National Cancer Institute. Available at: https://www.cancer.gov/about-cancer/understanding/what-is-cancer (Accessed: November 15, 2022).
[2]	Bailar, J. C., 3rd and Gornik, H. L. (1997) “Cancer undefeated,” The New England journal of medicine, 336(22), pp. 1569-1574.
[3]	Cancer Statistics (2015) National Cancer Institute. Available at: https://www.cancer.gov/about-cancer/understanding/statistics (Accessed: November 15, 2022).
[4]	Head and Neck Cancer—Patient Version (no date) National Cancer Institute. Available at: https://www.cancer.gov/types/head-and-neck (Accessed: November 28, 2022).
[5]	Bangladesh - Global Cancer Observatory (2020). Available at: https://gco.iarc.fr/today/data/factsheets/populations/50-bangladesh-fact-sheets.pdf (Accessed: November 28, 2022).
[6]	Shaikh, M. H. et al. (2017) “Prevalence and types of high-risk human papillomaviruses in head and neck cancers from Bangladesh,” BMC cancer, 17(1), pp. 1-11.
[7]	McCarthy, C. E. et al. (2015) “Trends and regional variation in the incidence of head and neck cancers in England: 2002 to 2011,” International journal of oncology, 47(1), pp. 204-210.
[8]	ESMO (no date) ESMO 2017 Press Release: KEYNOTE-040 Evaluates Pembrolizumab in Head and Neck Cancer, Esmo.org. Available at: https://www.esmo.org/newsroom/press-releases/keynote-040-evaluates-pembrolizumab-in-head-and-neck-cancer (Accessed: November 28, 2022).
[9]	Cohen, E.E., Soulières, D., Le Tourneau, C., Dinis, J., Licitra, L., Ahn, M.J., Soria, A., Machiels, J.P., Mach, N., Mehra, R. and Burtness, B., 2019. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet, 393(10167), pp.156-167.